Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 41.24 -4.05% -1.74
GTHX closed down 4.05 percent on Monday, October 15, 2018, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical GTHX trend table...

Date Alert Name Type % Chg
Oct 15 Fell Below 200 DMA Bearish 0.00%
Oct 15 Multiple of Ten Bullish Other 0.00%
Oct 15 Wide Bands Range Expansion 0.00%
Oct 15 Oversold Stochastic Weakness 0.00%
Oct 12 Narrow Range Bar Range Contraction -4.05%
Oct 12 NR7 Range Contraction -4.05%
Oct 12 Wide Bands Range Expansion -4.05%
Oct 12 Oversold Stochastic Weakness -4.05%
Oct 11 Wide Bands Range Expansion -4.09%
Oct 11 Oversold Stochastic Weakness -4.09%

Older signals for GTHX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Is GTHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.57
52 Week Low 18.035
Average Volume 310,936
200-Day Moving Average 41.6236
50-Day Moving Average 55.8494
20-Day Moving Average 50.8635
10-Day Moving Average 44.799
Average True Range 3.1227
ADX 39.15
+DI 9.1365
-DI 33.4792
Chandelier Exit (Long, 3 ATRs ) 59.0019
Chandelier Exit (Short, 3 ATRs ) 49.2781
Upper Bollinger Band 64.5238
Lower Bollinger Band 37.2032
Percent B (%b) 0.15
BandWidth 53.713567
MACD Line -4.5025
MACD Signal Line -3.4372
MACD Histogram -1.0653
Fundamentals Value
Market Cap 1.17 Billion
Num Shares 28.3 Million
EPS -11.02
Price-to-Earnings (P/E) Ratio -3.74
Price-to-Sales 0.00
Price-to-Book 4.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.47
Resistance 3 (R3) 45.50 44.11 44.77
Resistance 2 (R2) 44.11 43.04 44.10 44.53
Resistance 1 (R1) 42.68 42.37 41.99 42.65 44.29
Pivot Point 41.29 41.29 40.95 41.28 41.29
Support 1 (S1) 39.86 40.22 39.17 39.83 38.19
Support 2 (S2) 38.47 39.55 38.46 37.95
Support 3 (S3) 37.04 38.47 37.72
Support 4 (S4) 37.01